Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated
in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal
cancer (CRC). Dermatological reactions can cause significant physical and psycho-social
discomfort to patients. In the present study, the investigators evaluated the effect of
epidermal growth factor (EGF) ointment on EGFR inhibitor-related skin side effects (ERSEs).